As shown in Figure 2B, DC maturation appeared correlated to the clinical stage of disease, since the percentage of CD83+ DCs tended to increase progressively with the severity of breast cancer (carcinoma in situ: 4.31 ± 0.81; stage I: 4.91 ± 2.00; stage IIA: 5.11 ± 1.05; stage IIB: 5.46 ± 0.83). This evidence concerns the gene CD83 and breast cancer.